S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

$8.68
-0.14 (-1.59%)
(As of 02/23/2024 ET)
Today's Range
$8.16
$9.09
50-Day Range
$5.94
$9.74
52-Week Range
$2.82
$10.13
Volume
11.47 million shs
Average Volume
6.78 million shs
Market Capitalization
$2.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.92

Ardelyx MarketRank™ Stock Analysis

Analyst Rating
Buy
3.17 Rating Score
Upside/​Downside
42.4% Upside
$12.36 Price Target
Short Interest
Bearish
12.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.32
Upright™ Environmental Score
News Sentiment
0.25mentions of Ardelyx in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$2.56 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.27) to ($0.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.59 out of 5 stars

Medical Sector

148th out of 939 stocks

Pharmaceutical Preparations Industry

61st out of 437 stocks


ARDX stock logo

About Ardelyx Stock (NASDAQ:ARDX)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

ARDX Stock Price History

ARDX Stock News Headlines

3 mid-caps under $20 that Wall Street loves (ARDX)
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share
AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Where Ardelyx Stands With Analysts
The Retirement of Your Dreams Awaits You…
Imagine it's 2025 and you have the financial freedom to pursue any of your biggest goals. All of this because YOU decided to take action in 2024. The Bitcoin Halving in 2024 could change your life forever...And the strategies outlined in the Crypto Retirement Blueprint will give you what you need to be able to crush the upcoming halving cycle bull run, and potentially retire quickly in wealth.
Ardelyx: Q4 Earnings Snapshot
Ardelyx (ARDX) Scheduled to Post Quarterly Earnings on Thursday
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
KPTI May 2024 1.500 call
3 Revolutionary Biotech Stocks Poised for 10X Surge
ARDX Feb 2024 4.000 put
This Is What Whales Are Betting On Ardelyx
ARDX Jan 2024 11.000 call
See More Headlines
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
2/23/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ARDX
Employees
133
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$11.92
High Stock Price Target
$15.00
Low Stock Price Target
$8.50
Potential Upside/Downside
+34.2%
Consensus Rating
Buy
Rating Score (0-4)
3.17
Research Coverage
6 Analysts

Profitability

Net Income
$-67,210,000.00
Pretax Margin
-19.63%

Debt

Sales & Book Value

Annual Sales
$52.16 million
Book Value
$0.50 per share

Miscellaneous

Free Float
219,370,000
Market Cap
$2.06 billion
Optionable
Optionable
Beta
0.92

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report














ARDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Ardelyx stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings
or view top-rated stocks.

What is Ardelyx's stock price target for 2024?

7 brokers have issued 1-year price targets for Ardelyx's stock. Their ARDX share price targets range from $8.50 to $15.00. On average, they expect the company's stock price to reach $12.36 in the next year. This suggests a possible upside of 42.4% from the stock's current price.
View analysts price targets for ARDX
or view top-rated stocks among Wall Street analysts.

How have ARDX shares performed in 2024?

Ardelyx's stock was trading at $6.20 at the start of the year. Since then, ARDX stock has increased by 40.0% and is now trading at $8.68.
View the best growth stocks for 2024 here
.

When is Ardelyx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ARDX earnings forecast
.

How were Ardelyx's earnings last quarter?

Ardelyx, Inc. (NASDAQ:ARDX) issued its quarterly earnings data on Thursday, February, 22nd. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. The biopharmaceutical company had revenue of $34.36 million for the quarter, compared to the consensus estimate of $34.26 million. Ardelyx had a negative net margin of 19.79% and a negative trailing twelve-month return on equity of 19.75%. Ardelyx's revenue was down 22.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.06 EPS.

What ETFs hold Ardelyx's stock?

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (5.61%), Eventide Asset Management LLC (2.93%), Rubric Capital Management LP (1.73%), Price T Rowe Associates Inc. MD (1.00%), Price T Rowe Associates Inc. MD (1.00%) and Northern Trust Corp (0.94%). Insiders that own company stock include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends
.

How do I buy shares of Ardelyx?

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ARDX) was last updated on 2/23/2024 by MarketBeat.com Staff